Corbus Pharmaceuticals Holdings Shares Are Trading Lower Amid Sympathy With Novo Nordisk After the Company Reported Results From Its Phase2a Trial of Monlunabant in Obesity. Also, Wedbush Maintained an Outperform Rating on the Stock but Lowered Its...

科布斯製藥控股股票在同情諾和諾地低，因爲該公司在肥胖症的Monlunabant第2a期試驗結果公佈後交易下跌。此外，Wedbush維持對該股的跑贏大市評級，但下調...

Benzinga · 09/21 00:29

Corbus Pharmaceuticals Holdings Shares Are Trading Lower Amid Sympathy With Novo Nordisk After the Company Reported Results From Its Phase2a Trial of Monlunabant in Obesity. Also, Wedbush Maintained an Outperform Rating on the Stock but Lowered Its Price Target From $85 to $51.

Corbus Pharmaceuticals控股股份在諾華諾德報道其肥胖症2a期Monlunabant試驗結果後，股價低於其股價，引發同情情緒。此外，Wedbush維持了對該股的表現評級，但將其目標股價從85美元下調至51美元。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。